394-64-9

Basic information

• Product Name: 1-FLUORO-2,3-DIMETHOXYBENZENE
• Synonyms: 3-FLUOROVERATROLE;2,3-DIMETHOXY-1-FLUOROBENZENE;1-FLUORO-2,3-DIMETHOXYBENZENE
• CAS NO: 394-64-9
• Molecular Formula: C₈H₉FO₂
• Molecular Weight: 156.15
• Mol File: 394-64-9.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 96-97℃ (20 Torr)
• Flash Point: 66.5°C
• Appearance: /
• Density: 1.102g/cm³
• Vapor Pressure: 1.51mmHg at 25°C
• Refractive Index: 1.4948 (589.3 nm 22.5℃)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-FLUORO-2,3-DIMETHOXYBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-FLUORO-2,3-DIMETHOXYBENZENE(394-64-9)
• EPA Substance Registry System: 1-FLUORO-2,3-DIMETHOXYBENZENE(394-64-9)

Safety Data

• Hazardous Substances Data: 394-64-9(Hazardous Substances Data)

Usage

General Description

1-Fluoro-2,3-dimethoxybenzene is an organic chemical compound with the molecular formula C8H9FO2. It is a colorless liquid with a faint, sweet odor, and it is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. The compound contains a fluorine atom and two methoxy groups attached to a benzene ring, making it a versatile building block for the production of various organic compounds. 1-Fluoro-2,3-dimethoxybenzene is also used as a solvent and can react with other chemicals to form new compounds with different properties and uses. Overall, this chemical plays an important role in the field of organic synthesis and has diverse applications in the production of various commercial products.

InChI:InChI=1/C8H9FO2/c1-10-7-5-3-4-6(9)8(7)11-2/h3-5H,1-2H3

Upstream product

• 91-16-7 1,2-dimethoxybenzene 
• 73943-41-6 2-fluoro-6-methoxyphenol 
• 77-78-1 dimethyl sulfate 
• 96994-70-6 2-fluoro-6-hydroxyanisole 
• 456-49-5 1-fluoro-3-methoxybenzene 
• 74266-68-5 fluoro-3 methoxy-2 benzaldehhyde 
• 363-52-0 3-fluorocatechol 
• 74-88-4 methyl iodide 
• 103731-48-2 N-fluoro-N-(exo-2-norbornyl)-p-toluenesulfonamide 

Downstream Products

• 363-52-0 3-fluorocatechol 
• 1716-43-4 α-chloro-2-fluoro-3,4-dimethoxytoluene 
• 37686-68-3 2-fluoro-3,4-dimethoxybenzaldehyde 
• 71924-61-3 3-fluoro-4,5-dimethoxybenzaldehyde 
• 5150-42-5 2,3-dimethoxyphenol 
• 158641-45-3 1-(2-fluoro-3,4-dimethoxyphenyl)ethanone 
• 73943-41-6 2-fluoro-6-methoxyphenol 
• 96994-70-6 2-fluoro-6-hydroxyanisole 
• 2967-96-6 2-fluoro-3,4-dimethoxybenzoic acid 
• 158641-49-7 4-Ethyl-3-fluoro-benzene-1,2-diol 
• 158641-47-5 1-Ethyl-2-fluoro-3,4-dimethoxy-benzene 
• 158641-53-3 2-Bromo-1-(2-fluoro-3,4-dimethoxy-phenyl)-ethanone 
• 158641-61-3 2-[2-(2-Fluoro-3,4-dihydroxy-phenyl)-2-oxo-ethyl]-isoindole-1,3-dione 
• 158641-55-5 2-fluoro-3,4-dimethoxy-ω-phthalimidoacetophenone 

Relevant articles and documents

QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS

The present application relates to novel quinazoline compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.

ANTIBACTERIAL COMPOUNDS

The present Invention relates to cephalosporin antibacterial compounds of Formula (!): corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods for bacterial infections, especially those caused by gram-negative bacteria.

Discovery of a long-acting, peripherally selective inhibitor of catechol- O -methyltransferase

Novel nitrocatechol-substituted heterocycles were designed and evaluated for their ability to inhibit catechol-O-methyltransferase (COMT). Replacement of the pyrazole core of the initial hit 4 with a 1,2,4-oxadiazole ring resulted in a series of compounds endowed with longer duration of COMT inhibition. Incorporation of a pyridine N-oxide residue at position 3 of the 1,2,4-oxadiazole ring led to analogue 37f, which was found to possess activity comparable to entacapone and lower toxicity in comparison to tolcapone. Lead structure 37f was systematically modified in order to improve selectivity and duration of COMT inhibition as well as to minimize toxicity. Oxadiazole 37d (2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4, 6-dimethylpyridine 1-oxide (BIA 9-1067)) was identified as a long-acting, purely peripheral inhibitor, which is currently under clinical evaluation as an adjunct to l-Dopa therapy of Parkinson's disease.